Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy

Mult Scler. 2019 Jul;25(8):1196-1201. doi: 10.1177/1352458519832259. Epub 2019 Apr 9.

Abstract

A 31-year-old woman affected by multiple sclerosis (MS) experienced generalized tonic-clonic seizures 2 months after the second alemtuzumab cycle. Positive JC virus (JCV)-DNA in cerebrospinal fluid (CSF) and lesion iconography at magnetic resonance imaging (MRI) were suggestive of progressive multifocal leukoencephalopathy (PML). After 1 month, during full-blown immune reconstitution inflammatory syndrome, JCV-DNA became negative and symptoms gradually improved. New T- and B-cell output and T- and B-cell diversity were low and lymphocytes poorly responded to stimulation. This is the first case of an alemtuzumab-treated patient with clinical symptoms and radiological features compatible with PML. The lack of large T- and B-cell diversity, necessary for JCV recognition, is likely to have concurred to PML insurgence.

Keywords: B-cell receptor repertoire; KRECs; PML; T-cell receptor repertoire; TRECs; alemtuzumab.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alemtuzumab / adverse effects*
  • Female
  • Humans
  • Immunologic Factors / adverse effects*
  • Leukoencephalopathy, Progressive Multifocal / chemically induced*
  • Multiple Sclerosis / drug therapy*

Substances

  • Immunologic Factors
  • Alemtuzumab